Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADCT NASDAQ:AUPH NASDAQ:HRMY NASDAQ:HRTX NYSE:MYOV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$3.30+4.6%$2.62$1.05▼$4.13$312.41M1.89597,680 shs593,846 shsAUPHAurinia Pharmaceuticals$8.93+6.4%$8.04$5.20▼$10.67$1.13B1.161.40 million shs5.35 million shsHRMYHarmony Biosciences$34.33+0.1%$33.51$26.47▼$41.61$1.97B0.83633,504 shs569,367 shsHRTXHeron Therapeutics$2.22-0.4%$2.04$1.04▼$3.73$340.22M1.182.17 million shs827,084 shsMYOVMyovant Sciences$26.98$26.96$7.67▼$27.06$2.62B2.171.17 million shs2.26 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics+4.27%+18.10%-10.10%+171.19%+4.60%AUPHAurinia Pharmaceuticals+6.44%+18.03%+9.57%+20.51%+62.36%HRMYHarmony Biosciences+0.12%+6.98%-4.24%+17.69%+2.42%HRTXHeron Therapeutics-0.45%+2.54%+4.72%+16.23%-26.97%MYOVMyovant Sciences0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADCTADC Therapeutics1.5945 of 5 stars3.52.00.00.00.00.80.6AUPHAurinia Pharmaceuticals2.798 of 5 stars3.51.00.00.02.60.81.9HRMYHarmony Biosciences4.8146 of 5 stars4.51.00.00.03.33.34.4HRTXHeron Therapeutics3.9381 of 5 stars3.50.00.04.23.31.70.6MYOVMyovant SciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADCTADC Therapeutics 3.00Buy$7.75135.20% UpsideAUPHAurinia Pharmaceuticals 3.00Buy$11.5028.78% UpsideHRMYHarmony Biosciences 3.00Buy$51.3349.53% UpsideHRTXHeron Therapeutics 3.00Buy$5.00125.23% UpsideMYOVMyovant Sciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ADCT, MYOV, HRTX, HRMY, and AUPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025HRMYHarmony BiosciencesDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$54.00 ➝ $55.007/10/2025HRMYHarmony BiosciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$33.006/20/2025ADCTADC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$8.00 ➝ $5.006/13/2025ADCTADC TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $10.006/9/2025HRTXHeron TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.006/2/2025HRMYHarmony BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$61.005/15/2025ADCTADC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.005/15/2025HRMYHarmony BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$44.00 ➝ $48.005/13/2025HRMYHarmony BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/6/2025HRMYHarmony BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$49.00 ➝ $49.004/28/2025HRMYHarmony BiosciencesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $48.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADCTADC Therapeutics$70.84M4.61N/AN/A($2.10) per share-1.57AUPHAurinia Pharmaceuticals$235.13M5.13$0.33 per share27.20$2.68 per share3.33HRMYHarmony Biosciences$714.73M2.76$2.95 per share11.64$11.56 per share2.97HRTXHeron Therapeutics$148.52M2.28N/AN/A($0.22) per share-10.09MYOVMyovant Sciences$230.97M11.36N/AN/A($5.04) per share-5.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADCTADC Therapeutics-$157.85M-$1.45N/AN/AN/A-197.64%N/A-45.57%8/5/2025 (Estimated)AUPHAurinia Pharmaceuticals$5.75M$0.2831.8915.95N/A16.11%14.27%9.93%7/30/2025 (Estimated)HRMYHarmony Biosciences$145.49M$2.6213.1011.040.5120.53%24.32%15.92%8/5/2025 (Estimated)HRTXHeron Therapeutics-$13.58M-$0.06N/AN/AN/A-5.24%N/A-3.43%8/5/2025 (Estimated)MYOVMyovant Sciences-$205.98M-$1.91N/AN/AN/A-48.47%N/A-39.36%N/ALatest ADCT, MYOV, HRTX, HRMY, and AUPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025AUPHAurinia Pharmaceuticals$0.18N/AN/AN/A$64.27 millionN/A8/5/2025Q2 2025ADCTADC Therapeutics-$0.36N/AN/AN/A$17.82 millionN/A8/5/2025Q2 2025HRMYHarmony Biosciences$0.78N/AN/AN/A$204.37 millionN/A8/5/2025Q2 2025HRTXHeron Therapeutics-$0.01N/AN/AN/A$38.08 millionN/A5/14/2025Q1 2025ADCTADC Therapeutics-$0.38-$0.36+$0.02-$0.36$17.71 million$23.03 million5/12/2025Q1 2025AUPHAurinia Pharmaceuticals$0.08$0.16+$0.08$0.16$61.06 million$62.47 million5/6/2025Q1 2025HRMYHarmony Biosciences$0.59$0.78+$0.19$0.78$184.26 million$184.73 million5/6/2025Q1 2025HRTXHeron Therapeutics-$0.01$0.01+$0.02$0.01$37.08 million$38.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADCTADC TherapeuticsN/AN/AN/AN/AN/AAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/AMYOVMyovant SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADCTADC TherapeuticsN/A4.464.16AUPHAurinia Pharmaceuticals0.165.935.26HRMYHarmony Biosciences0.223.673.63HRTXHeron TherapeuticsN/A2.401.76MYOVMyovant SciencesN/A1.571.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADCTADC Therapeutics41.10%AUPHAurinia Pharmaceuticals36.83%HRMYHarmony Biosciences86.23%HRTXHeron Therapeutics80.01%MYOVMyovant Sciences30.62%Insider OwnershipCompanyInsider OwnershipADCTADC Therapeutics5.40%AUPHAurinia Pharmaceuticals12.20%HRMYHarmony Biosciences23.60%HRTXHeron Therapeutics5.86%MYOVMyovant Sciences1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADCTADC Therapeutics31099.18 million93.82 millionOptionableAUPHAurinia Pharmaceuticals300135.10 million118.62 millionOptionableHRMYHarmony Biosciences20057.42 million43.87 millionOptionableHRTXHeron Therapeutics300152.56 million143.62 millionOptionableMYOVMyovant Sciences40797.24 million95.39 millionNot OptionableADCT, MYOV, HRTX, HRMY, and AUPH HeadlinesRecent News About These CompaniesMyovant Sciences Stock Price HistoryJune 2, 2025 | investing.comMyovant Investor Claiming Skadden Conflict Denied Appellate RedoFebruary 21, 2025 | news.bloomberglaw.comNMyovant Investor Claiming Skadden Conflict Seeks Appellate RedoFebruary 14, 2025 | news.bloomberglaw.comNMyovant Investor Fails to Revive Skadden Conflict Suit on AppealJanuary 31, 2025 | news.bloomberglaw.comNSkadden-Myovant Appeals Court Skeptical of 'Family' ConflictJanuary 14, 2025 | news.bloomberglaw.comNgears of horus max winDecember 28, 2024 | bweducation.businessworld.inBVivek Ramaswamy Net Worth 2024: How He Built a Billion-Dollar EmpireNovember 13, 2024 | blackstarnews.comBVivek Ramaswamy's Net Worth: How Donald Trump's Key Aide Made His BillionsNovember 13, 2024 | msn.comBorn To Indian Immigrants, Now Part Of Trump's 'DOGE' Plan – How Vivek Ramaswamy Became A Billionaire By Shedding Unprofitable Pharma AssetsNovember 13, 2024 | msn.com18-year-old Vivek Ramaswamy's powerful commencement address goes viral | WATCHNovember 13, 2024 | english.mathrubhumi.comEVivek Ramaswamy’s Net Worth: A Young Billionaire Championing Capitalism and EfficiencyNovember 13, 2024 | newsx.comNWho Is Vivek Ramaswamy? Biotech Entrepreneur Appointed In Trump 2.0 Alongside Elon MuskNovember 13, 2024 | newsx.comNGlobal Hormone-Sensitive Advanced Prostate Cancer Treatment Market Expected to Reach USD 24.94 Billion by 2033 with a 7.2% CAGROctober 30, 2024 | fmiblog.comFGlobal Prostate Cancer Diagnostics Market to Observe Stunning Growth at a CAGR of ~12% by 2030 | DelveInsightSeptember 25, 2024 | finance.yahoo.comElinzanetant Shows Significant Improvement in Menopausal Vasomotor and Sleep SymptomsSeptember 20, 2024 | medscape.comMLong-Term Data Support Non-Hormonal Drug for Hot-Flash ManagementSeptember 15, 2024 | medpagetoday.comMForendo joins race to develop endometriosis drugsSeptember 12, 2024 | pharmaphorum.comPThe Scientific Establishment Is Turning 'Science' Into a Dogmatic Tool of Oppression | OpinionSeptember 11, 2024 | newsweek.comNProbability in the Engineering and Informational SciencesSeptember 10, 2024 | cambridge.orgCFDA clears Myovant's relugolix for uterine fibroids, setting up AbbVie clashAugust 29, 2024 | pharmaphorum.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADCT, MYOV, HRTX, HRMY, and AUPH Company DescriptionsADC Therapeutics NYSE:ADCT$3.30 +0.15 (+4.60%) Closing price 07/10/2025 03:59 PM EasternExtended Trading$3.27 -0.02 (-0.76%) As of 05:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Aurinia Pharmaceuticals NASDAQ:AUPH$8.93 +0.54 (+6.44%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$8.93 +0.00 (+0.04%) As of 04:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Harmony Biosciences NASDAQ:HRMY$34.33 +0.04 (+0.12%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$34.33 0.00 (0.00%) As of 07/10/2025 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Heron Therapeutics NASDAQ:HRTX$2.22 -0.01 (-0.45%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$2.22 0.00 (0.00%) As of 07/10/2025 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Myovant Sciences NYSE:MYOVMyovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.